MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $34.45 Million Stock Position in DexCom, Inc. (NASDAQ:DXCM)

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lessened its stake in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 2.8% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 443,001 shares of the medical device company's stock after selling 12,694 shares during the quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. owned approximately 0.11% of DexCom worth $34,452,000 as of its most recent filing with the SEC.

Other large investors have also modified their holdings of the company. Czech National Bank grew its position in shares of DexCom by 3.7% in the 4th quarter. Czech National Bank now owns 84,689 shares of the medical device company's stock worth $6,586,000 after acquiring an additional 3,057 shares in the last quarter. Capital Investment Advisors LLC bought a new stake in DexCom during the fourth quarter valued at $206,000. Cullen Investment Group LTD. lifted its position in shares of DexCom by 5.6% in the 4th quarter. Cullen Investment Group LTD. now owns 11,502 shares of the medical device company's stock worth $895,000 after buying an additional 614 shares during the last quarter. 180 Wealth Advisors LLC acquired a new position in shares of DexCom in the 4th quarter valued at about $255,000. Finally, Cardinal Point Capital Management ULC acquired a new position in shares of DexCom in the 4th quarter valued at about $249,000. Institutional investors own 97.75% of the company's stock.

Insiders Place Their Bets

In other news, COO Jacob Steven Leach sold 14,076 shares of DexCom stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total value of $990,668.88. Following the transaction, the chief operating officer now directly owns 313,497 shares in the company, valued at approximately $22,063,918.86. The trade was a 4.30% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Kevin R. Sayer sold 32,498 shares of the stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total value of $2,287,209.24. Following the sale, the chief executive officer now owns 372,029 shares of the company's stock, valued at approximately $26,183,401.02. The trade was a 8.03% decrease in their position. The disclosure for this sale can be found here. Insiders sold 66,926 shares of company stock valued at $4,734,384 over the last ninety days. Corporate insiders own 0.32% of the company's stock.

DexCom Trading Up 1.4%

Shares of DXCM stock traded up $1.19 during trading hours on Monday, reaching $86.67. 567,260 shares of the stock traded hands, compared to its average volume of 4,188,337. The business has a fifty day moving average price of $72.01 and a 200 day moving average price of $77.69. The company has a quick ratio of 1.28, a current ratio of 1.47 and a debt-to-equity ratio of 0.59. DexCom, Inc. has a 1-year low of $57.52 and a 1-year high of $132.09. The firm has a market capitalization of $33.98 billion, a PE ratio of 60.62, a PEG ratio of 2.30 and a beta of 1.43.

DexCom (NASDAQ:DXCM - Get Free Report) last issued its earnings results on Thursday, May 1st. The medical device company reported $0.32 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.33 by ($0.01). DexCom had a net margin of 14.29% and a return on equity of 30.14%. The company had revenue of $1.04 billion for the quarter, compared to analyst estimates of $1.02 billion. During the same period last year, the business earned $0.32 EPS. The company's quarterly revenue was up 12.5% on a year-over-year basis. On average, equities research analysts forecast that DexCom, Inc. will post 2.03 EPS for the current year.

Wall Street Analysts Forecast Growth

DXCM has been the topic of several research reports. Canaccord Genuity Group increased their price objective on shares of DexCom from $103.00 to $106.00 and gave the stock a "buy" rating in a research note on Friday, May 2nd. Citigroup raised their price target on DexCom from $101.00 to $104.00 and gave the stock a "buy" rating in a report on Tuesday, March 4th. Cfra Research upgraded DexCom to a "hold" rating in a research report on Friday, March 21st. Redburn Atlantic raised DexCom from a "neutral" rating to a "buy" rating and increased their target price for the stock from $85.00 to $115.00 in a research report on Monday, February 3rd. Finally, Piper Sandler reduced their price target on shares of DexCom from $100.00 to $90.00 and set an "overweight" rating for the company in a report on Friday, May 2nd. Five equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and three have issued a strong buy rating to the company's stock. Based on data from MarketBeat, DexCom presently has an average rating of "Moderate Buy" and an average price target of $98.11.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.